USD 7.04
(1.15%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 221.83 Million USD | -46.32% |
2022 | 413.25 Million USD | 1754.58% |
2021 | 22.28 Million USD | 34.9% |
2020 | 16.51 Million USD | -1.49% |
2019 | 16.76 Million USD | 0.0% |
2001 | 413.25 Million USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 452.26 Million USD | 0.0% |
2024 Q1 | 234.49 Million USD | 0.0% |
2023 FY | 221.83 Million USD | -46.32% |
2023 Q4 | 221.83 Million USD | -45.04% |
2023 Q2 | 410.93 Million USD | 1.69% |
2023 Q1 | 404.09 Million USD | -2.22% |
2023 Q3 | 403.66 Million USD | -1.77% |
2022 Q4 | 413.25 Million USD | 590.58% |
2022 Q3 | 59.84 Million USD | 16.1% |
2022 Q2 | 51.54 Million USD | 88.75% |
2022 FY | 413.25 Million USD | 1754.58% |
2022 Q1 | 27.3 Million USD | 22.56% |
2021 Q1 | 16.43 Million USD | -0.48% |
2021 FY | 22.28 Million USD | 34.9% |
2021 Q4 | 22.28 Million USD | 36.97% |
2021 Q3 | 16.26 Million USD | -0.55% |
2021 Q2 | 16.35 Million USD | -0.49% |
2020 FY | 16.51 Million USD | -1.49% |
2020 Q1 | - USD | 0.0% |
2020 Q4 | 16.51 Million USD | 0.0% |
2019 FY | 16.76 Million USD | 0.0% |
2001 FY | 413.25 Million USD | 0.0% |
2001 Q4 | 22.28 Million USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
ADC Therapeutics SA | 112.73 Million USD | -96.784% |
Alto Neuroscience, Inc. | 151.33 Million USD | -46.582% |
Annovis Bio, Inc. | - USD | -Infinity% |
Biohaven Pharmaceutical Holding Company Ltd. | 27.56 Million USD | -704.654% |
Nuvation Bio Inc. | 2.03 Million USD | -10800.983% |
Nuvation Bio Inc. | 2.03 Million USD | -10800.983% |
Arcus Biosciences, Inc. | 110 Million USD | -101.668% |
Zymeworks Inc. | 22.46 Million USD | -887.645% |